REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat lymphoma: experimental drug tegavivint enters human testing
Disease control Recruiting nowThis early-stage trial is testing a drug called tegavivint in about 18 adults whose large B-cell lymphoma has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Tegavivint works by blocking certain protein…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated May 26, 2026 09:30 UTC
-
New 5-Drug cocktail ViPOR targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve co…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New combo may help more lymphoma patients qualify for potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help more people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to control the disease so patients can proceed to CAR-T, whi…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:48 UTC